A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions

Head Lice Infestation

Interventions

DRUG

Ha44 Gel 0.74% w/w

HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.

Trial Locations (2)

Axis Clinical Trials, Los Angeles

Universal Biopharma Research Institute, Dinuba